Affiliation:
1. All India Institute of Medical Sciences, Kalyani, West Bengal, India
Abstract
Meningiomas are the most common primary intracranial tumors in adults comprising about one-third of cases. Most of them are slow-growing and follow a benign course. However, some may behave aggressively with recurrence and even metastasis. Histopathological features have long been regarded as the gold standard for diagnosis, grading, and prognostication. Advances in genomics and molecular characteristics of meningiomas have uncovered the potential use of many biomarkers for more accurate grading and prediction of prognosis and recurrence. Precision clinical trials are needed to utilize these biomarkers for targeted therapy. The present review is a snapshot of some of these important updates in meningioma as per the 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5).
Publisher
IP Innovative Publication Pvt Ltd
Reference15 articles.
1. Ostrom Q T, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.Neuro Oncol 2017;19(Suppl 5):1-88
2. Louis DN, Sahm F, Perry A, Deimling A Von, EB Claus, Meningiomas MC, WHO Classification of Tumours Editorial Board. Central nervous system tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2021 [cited 2024-06-12]. (WHO classification of tumours series, 5th ed.; vol. 6). ..
3. Chen WC, Choudhury A, Youngblood MW, Polley MC, Lucas CG, Mirchia K, Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.Nat Med 2009;29(12):3067-76
4. Radiographic prediction of meningioma grade by semantic and radiomic features
5. Integrated models incorporating radiologic and radiomic features predict meningioma grade, local failure, and overall survival